Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 24

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 24
---
 (4502)

Earnings Report ( Kessan Tanshin ) for the Nine-month

Period Ended December 31, 2024 (Consolidated)

|                                              |     | JPY (millions) | As of March 31, 2024 |     |     | As of December 31, 2024 |
|:---------------------------------------------|:----|:---------------|---------------------:|:----|:----|------------------------:|
| EQUITY                                       |     |                |                      |     |     |                         |
| Share capital                                |     |                |            1,676,596 |     |     |               1,694,660 |
| Share premium                                |     |                |            1,747,414 |     |     |               1,755,999 |
| Treasury shares                              |     |                |              -51,259 |     |     |                 -24,835 |
| Retained earnings                            |     |                |            1,391,203 |     |     |               1,290,948 |
| Other components of equity                   |     |                |            2,509,310 |     |     |               2,701,502 |
| Equity attributable to owners of the Company |     |                |            7,273,264 |     |     |               7,418,274 |
| Non-controlling interests                    |     |                |                  741 |     |     |                     917 |
| Total equity                                 |     |                |            7,274,005 |     |     |               7,419,191 |
| Total liabilities and equity                 |     |                |           15,108,792 |     |     |              15,106,844 |

<div align='center'>18</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Nine-month

Period Ended December 31, 2024 (Consolidated)

(4) Condensed Interim Consolidated Statements of Changes in Equity

Nine-month period ended December 31, 2023 (From April 1 to December 31, 2023)

|                                            |     | JPY (millions)                               |           |     |                                                                                                     |           |     |          |          |     |          |           |     |                            |           |     |        |
|                                            |     | Equity